SCHEMBL742785

SCHEMBL742785

O=C(O)CCC(C(=O)O)C(=O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 12/20 0.54
TET2 Q6N021 3/20 0.50
KDM4A O75164 2/20 0.50
KDM4C Q9H3R0 2/20 0.50
KDM2A Q9Y2K7 2/20 0.50
TET3 O43151 1/20 0.50
CYP1A2 P05177 2/20 0.48
GRM3 Q14832 2/20 0.48
GRM8 O00222 1/20 0.48
GRM6 O15303 1/20 0.48
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GSR P00390 1/20 0.48
GRIK1 P39086 1/20 0.48
GRM5 P41594 1/20 0.48
GRIA1 P42261 1/20 0.48
GRIA2 P42262 1/20 0.48
GRIA3 P42263 1/20 0.48
SLC1A3 P43003 1/20 0.48
SLC1A2 P43004 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10603309 0.85 LMNA (0.46) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL669817 0.83 FOLH1 (0.64) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL27473595 0.78 FOLH1 (0.58) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL509039 0.74 FOLH1 (0.54) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL11056280 0.74 TET2 (0.64) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL7000281 0.74 CYP1A2 (0.54) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL1377274 0.74 CYP1A2 (0.54) FOLH1TET2KDM4AKDM4CKDM2A
SCHEMBL4321051 0.72 TDP1 (0.48) FOLH1TET2TET3GRIK1GRIK2
SCHEMBL1052505 0.72 TDP1 (0.48) FOLH1TET2TET3GRIK1GRIK2
SCHEMBL301073 0.72 CYP1A2 (0.65) TET2KDM4AKDM4CKDM2ATET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1588736-A2 Microperfusive electrical stimulation Zoll Medical Corporation (US) 2005-10-26 EP claimed
EP-4642757-A1 PROCESS FOR TREATING KERATIN MATERIALS USING AT LEAST ONE OIL BEARING ACETOACETATE FUNCTIONS AND AT LEAST ONE CROSSLINKING AGENT L'OREAL (FR) 2025-11-05 EP disclosed
EP-4642759-A1 PROCESS FOR TREATING KERATIN FIBRES USING AT LEAST ONE OIL BEARING ACETOACETATE FUNCTIONS L'OREAL (FR) 2025-11-05 EP disclosed
WO-2025109174-A1 COMPOSITION IN THE FORM OF A DIRECT EMULSION COMPRISING AT LEAST ONE COMPOUND BEARING ACETOACETATE FUNCTIONS, AT LEAST ONE FATTY ACID AND AT LEAST CHITOSAN L'OREAL (FR) 2025-05-30 WO disclosed
WO-2024141523-A1 PROCESS FOR TREATING KERATIN FIBRES USING AT LEAST ONE OIL BEARING ACETOACETATE FUNCTIONS L'OREAL (FR) 2024-07-04 WO disclosed
WO-2024141524-A1 PROCESS FOR TREATING KERATIN MATERIALS USING AT LEAST ONE OIL BEARING ACETOACETATE FUNCTIONS AND AT LEAST ONE CROSSLINKING AGENT L'OREAL (FR) 2024-07-04 WO disclosed
US-8663342-B2 Process for producing nitrogen-containing composition MITSUBISHI CHEMICAL CORPORATION (JP) 2014-03-04 US disclosed
EP-2685259-A1 A method of diagnosing an asthma disease state The Governors of the University of Alberta (CA) 2014-01-15 EP disclosed
EP-2331955-B1 Diagnosis of an asthma disease state UNIV ALBERTA (CA) 2013-10-30 EP disclosed
US-20130177495-A1 NITROGEN-CONTAINING COMPOSITION AND PROCESS FOR PRODUCING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2013-07-11 US disclosed
EP-2431071-A1 Microperfusive electrical stimulation Zoll Medical Corporation (US) 2012-03-21 EP disclosed
US-20110238319-A1 METHOD OF DIAGNOSING A RESPIRATORY DISEASE THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2011-09-29 US disclosed
EP-2331955-A1 A METHOD OF DIAGNOSING A RESPIRATORY DISEASE The Governors of the University of Alberta (CA) 2011-06-15 EP disclosed
WO-2010020058-A1 A METHOD OF DIAGNOSING A RESPIRATORY DISEASE THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2010-02-25 WO disclosed
EP-1199368-B1 Use of adenoviral e4 reading frames to improve expression of a gene of interest TRANSGENE SA (FR) 2004-01-21 EP disclosed
US-6475480-B1 Use of adenoviral E4 reading frames to improve expression of a gene of interest TRANSGENE S.A. (FR) 2002-11-05 US disclosed
EP-0974668-B1 Use of adenoviral E4 reading frames to improve expression of a gene of interest TRANSGENE SA (FR) 2002-10-02 EP disclosed
EP-1199368-A2 Use of adenoviral e4 reading frames to improve expression of a gene of interest TRANSGENE S.A. (FR) 2002-04-24 EP disclosed
EP-0974668-A1 Use of adenoviral E4 reading frames to improve expression of a gene of interest TRANSGENE S.A. (FR) 2000-01-26 EP disclosed